导管定向溶栓对比单用抗凝治疗中高危肺栓塞的系统综述与荟萃分析
结果显示导管定向溶栓与较低的全因死亡风险相关,且未观察到颅内出血风险有统计学显著增加。
要点
- 导管定向溶栓与单用抗凝相比,全因死亡风险更低。
- 两组在大出血和颅内出血方面未见统计学显著差异。
- 基线右室/左室比值越大,导管定向溶栓的死亡获益可能越弱。
核心结论
- 在中高危肺栓塞患者中,导管定向溶栓相比单用抗凝与较低的全因死亡率相关,且未显示颅内出血风险统计学显著增加。
研究设计与样本
- 按照PRISMA指南开展系统综述与荟萃分析,检索PubMed、Scopus、Cochrane Library、Epistemonikos和ProQuest,截止日期为2026年5月8日。
主要发现
- 导管定向溶栓相比单用抗凝的全因死亡RR为0.41,95%CI为0.32至0.54,p<0.0001,I²=0%。
- 大出血RR为1.78,95%CI为0.85至3.71,p=0.1259,I²=51.3%,差异无统计学意义。
- 剪补法分析后大出血调整RR为0.84,95%CI为0.39至1.79,结果仍不显著。
- 肺栓塞相关死亡、颅内出血、右室/左室比值变化、血栓负荷评分变化和肺动脉收缩压在两组间表现相当。
- 荟萃回归提示基线右室/左室比值越大,观察到的死亡获益越小。
关键数值与推荐
- 导管定向溶栓与单用抗凝相比,全因死亡RR为0.41,95%CI为0.32至0.54,p<0.0001,I²=0%。
临床怎么用
- 中高危肺栓塞患者中,导管定向溶栓可作为降低全因死亡风险的再灌注策略考虑。
- 对于基线右室/左室比值较高的患者,应谨慎预期导管定向溶栓的死亡获益。
局限性
- 纳入研究包含观察性研究,可能存在混杂偏倚。
- 大出血结局的异质性较高(I²=51.3%),结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background Catheter-directed thrombolysis (CDT) has emerged as a reperfusion strategy for intermediate-risk and high-risk pulmonary embolism (PE), potentially improving thrombus resolution while reducing bleeding risk compared with systemic thrombolysis. However, evidence comparing CDT with anticoagulation alone remains inconsistent. Objective To evaluate the efficacy and safety of CDT compared with anticoagulation alone in intermediate-risk and high-risk PE. Methods A systematic review and meta-analysis was conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. PubMed, Scopus, Cochrane Library, Epistemonikos and ProQuest were searched through 8 May 2026. Randomised and observational studies comparing CDT with anticoagulation alone were included. Primary outcomes were all-cause mortality and major bleeding. Random-effects models were used to calculate pooled risk ratios (RRs) and mean differences with 95% CIs. Results 18 studies involving 16 126 patients were included. CDT was associated with a lower risk of all-cause mortality compared with anticoagulation alone (RR 0.41, 95% CI 0.32 to 0.54; p<0.0001; I²=0%). No statistically significant difference was observed in major bleeding (RR 1.78, 95% CI 0.85 to 3.71; p=0.1259; I²=51.3%), and trim-and-fill analysis yielded a similarly non-significant result (adjusted RR 0.84, 95% CI 0.39 to 1.79). CDT and anticoagulation alone showed comparable outcomes for PE-related mortality, intracranial haemorrhage, delta right ventricle (RV)/left ventricle (LV) ratio, delta Thrombus Burden Score or systolic pulmonary artery pressure. Meta-regression identified that a greater baseline RV/LV ratio was associated with attenuation of the observed mortality benefit. Conclusions CDT was associated with lower all-cause mortality compared with anticoagulant alone in intermediate-risk and high-risk PE without a statistically significant increase in intracranial haemorrhage. Larger adequately powered randomised trials are needed to define the role of CDT in acute PE. PROSPERO registration number CRD420261373193.
引用
- Open Heart:Catheter-directed thrombolysis versus anticoagulation for intermediate-risk and high-risk pulmonary embolism: a systematic review and meta-analysis
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。